362 related articles for article (PubMed ID: 15699480)
1. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
Lee AY; Rickles FR; Julian JA; Gent M; Baker RI; Bowden C; Kakkar AK; Prins M; Levine MN
J Clin Oncol; 2005 Apr; 23(10):2123-9. PubMed ID: 15699480
[TBL] [Abstract][Full Text] [Related]
2. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Couturaud F; Julian JA; Kearon C
Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
[TBL] [Abstract][Full Text] [Related]
4. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).
Kakkar AK; Levine MN; Kadziola Z; Lemoine NR; Low V; Patel HK; Rustin G; Thomas M; Quigley M; Williamson RC
J Clin Oncol; 2004 May; 22(10):1944-8. PubMed ID: 15143088
[TBL] [Abstract][Full Text] [Related]
5. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
[TBL] [Abstract][Full Text] [Related]
6. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
Nishioka J; Goodin S
J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
[TBL] [Abstract][Full Text] [Related]
7. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.
Monreal M; Lafoz E; Olive A; del Rio L; Vedia C
Thromb Haemost; 1994 Jan; 71(1):7-11. PubMed ID: 8165649
[TBL] [Abstract][Full Text] [Related]
8. The effect of low molecular weight heparin on survival in patients with advanced malignancy.
Klerk CP; Smorenburg SM; Otten HM; Lensing AW; Prins MH; Piovella F; Prandoni P; Bos MM; Richel DJ; van Tienhoven G; Büller HR
J Clin Oncol; 2005 Apr; 23(10):2130-5. PubMed ID: 15699479
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated thrombosis: focus on extended therapy with dalteparin.
Bick RL
J Support Oncol; 2006 Mar; 4(3):115-20. PubMed ID: 16553136
[TBL] [Abstract][Full Text] [Related]
10. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis.
Siragusa S; Cosmi B; Piovella F; Hirsh J; Ginsberg JS
Am J Med; 1996 Mar; 100(3):269-77. PubMed ID: 8629671
[TBL] [Abstract][Full Text] [Related]
11. Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases.
Pineo GF; Hull RD
Eur J Med Res; 2004 Apr; 9(4):215-24. PubMed ID: 15210402
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion.
Bechtold H; Gunzenhauser D; Sawitzki H; Fung S; Janssen D
Z Kardiol; 2003 Jul; 92(7):532-9. PubMed ID: 12883837
[TBL] [Abstract][Full Text] [Related]
13. Long-term clinical follow-up in 265 patients with deep venous thrombosis initially treated with either unfractionated heparin or dalteparin: a retrospective analysis.
Holmström M; Aberg W; Lockner D; Paul C
Thromb Haemost; 1999 Oct; 82(4):1222-6. PubMed ID: 10544902
[TBL] [Abstract][Full Text] [Related]
14. Dalteparin: new indication. Prophylaxis in medical patients: no advance.
Prescrire Int; 2005 Feb; 14(75):14-5. PubMed ID: 15751168
[TBL] [Abstract][Full Text] [Related]
15. Treatment of venous thromboembolism in cancer patients.
Levine MN; Lee AY
Semin Thromb Hemost; 1999; 25(2):245-9. PubMed ID: 10357092
[TBL] [Abstract][Full Text] [Related]
16. Warfarin versus low-molecular-weight heparin therapy in cancer patients.
Zacharski LR; Prandoni P; Monreal M
Oncologist; 2005 Jan; 10(1):72-9. PubMed ID: 15632254
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
[TBL] [Abstract][Full Text] [Related]
18. [Prevention of venous thromboembolism in internal medicine and neurology].
Malý J; Dulícek P; Penka M; Malý R; Gumulec J
Vnitr Lek; 2006 Mar; 52 Suppl 1():63-7. PubMed ID: 16637452
[TBL] [Abstract][Full Text] [Related]
19. Low-molecular-weight heparin or oral anticoagulation for secondary prevention of deep vein thrombosis in cancer patients.
Levine M
Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():9-11. PubMed ID: 14730472
[TBL] [Abstract][Full Text] [Related]
20. Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
Goodin S
Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S10-3. PubMed ID: 16286363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
